Notice
Notice
Retatrutide (GLP-1 + GIP + Glucagon) - Triple Metabolic Reset Weight Loss Program
Retatrutide (GLP-1 + GIP + Glucagon) - Triple Metabolic Reset Weight Loss Program
Compounded Retatrutide is a next-generation triple agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. Physiologically, it strongly suppresses appetite and slows gastric emptying via GLP-1 and GIP pathways while the glucagon receptor activation increases energy expenditure, enhances lipolysis, and improves fat oxidation in the liver and adipose tissue. These combined actions result in superior weight loss, significant reduction in visceral and total body fat, better insulin sensitivity, and preserved lean muscle mass compared to dual agonists (tirzepatide). This is THE FUTURE of weight loss.
Next-generation triple pathway fat loss, muscle maintenance and energy support.
- GLP-1 + GIP + Glucagon Retatrutide Weight Loss Program
- Higher energy expendinture support
- Improved lean muscle mass maintenance compared to earlier GLP-1s
- Lower dosing protocols often means vials last longer than other weight loss counterparts
Weight Loss Without Extreme Diets
Reach your goal weight without crash diets — steady, sustainable fat loss that actually lasts.
Shed Stubborn Fat & Maintain Results
Promote a balanced metabolism that helps you feel more energized and keep the weight off for good.
Control Cravings & Feel Fuller Longer
Curb hunger and stay satisfied between meals, so eating less feels effortless.
Boost Energy Levels Through The Roof
Enjoy elevated energy levels that keep you active, focused, and motivated all day.
Vitali-T vs The Competition
Expert Strategies for Lasting Change
Weight Gain
Tiredness
Sluggishness
Poor Sleep
Sweet Cravings
Low Energy
Body Aches
Weakness
FAQ
How does retatrutide work?
How does retatrutide work?
Triple agonist that activates GLP-1, GIP, and glucagon receptors to reduce appetite, slow digestion, and boost calorie burning.
How much weight can you lose?
How much weight can you lose?
Average 24-28% body weight loss (up to 28.3% in recent Phase 3 trials).
How is it taken?
How is it taken?
Once-weekly subcutaneous injection. Starts low, titrates up to 4-12 mg.
What are the main side effects?
What are the main side effects?
Though rare with this newer GLP-1: Nausea, vomiting, diarrhea, constipation (usually mild and improve with time).
How does it compare to tirzepatide?
How does it compare to tirzepatide?
Stronger weight loss (24-29% vs ~22%) due to added glucagon activation.
When will it be available?
When will it be available?
Not yet approved. Possible FDA approval late 2026 or 2027. Currently only in trials.
Does it help with blood sugar?
Does it help with blood sugar?
Yes. It improves blood sugar control and lowers HbA1c, making it promising for type 2 diabetes.